Home » Newsletters » BioWorld Science

BioWorld Science

March 2, 2007

View Archived Issues

New therapeutic agents for cancer covered in recent patents

Novel vaccine may be useful to treat familial ALS

Merck Frosst and Nippon Soda patents disclose new agents for treating eye disorders

Recent patents claim novel therapeutic agents for inflammatory disorders

Lithium starts clinical evaluation for the treatment of spinal cord injury

AT-101 monotherapy induces responses in hormone-refractory prostate cancer

Addition of oblimersen to docetaxel may not be beneficial in advanced prostate cancer

Epix reviews 2006 accomplishments

Alpharadin improves survival in hormone-refractory prostate cancer

CCR5: a novel target for asthma therapy

Advancis discusses Amoxicillin PULSYS refusal to file letter with FDA

Migraine prophylaxis compound BF-1 completes first clinical trial

Fenretinide receives orphan drug designations in U.S. and E.U.

Xoma collaborations take new directions

Futura Medical announces DermaSys as brand name for gel technology

Evotec and Interprotein collaborate on IL-6 inhibitor program

TG-100801 completes first phase I study for macular degeneration

PPD acquires exclusive license to novel Ranbaxy statin

Davanat filed for E.U. orphan drug status, advancing in phase II trials

Jerini plans Q3 NDA submission for icatibant in HAE

Second part of phase I study investigates R-7128 in HCV genotype 1 patients

Enrollment completed in phase II trials of Uvidem in melanoma

Accentia acquires rights to Revimmune

Positive interim results for Albuferon in treatment-naive chronic HCV genotype 1

Preliminary progression-free survival data from phase III study of MyVax

Neumune increases survival in primates with acute radiation syndrome

Levemir approved in E.U. in combination with oral antidiabetic drugs

Prevenar recommended for E.U. approval for pneumonia and acute otitis media

Vaprisol approved for treatment of hypervolemic hyponatremia

Tykerb studied in phase III trial for head and neck cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...